8c8b: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
New page: '''Unreleased structure''' The entry 8c8b is ON HOLD Authors: Yosaatmadja, Y., Newman, J.A., Baddock, H.T., Bielinski, M., von Delft, F., Bountra, C., McHugh, P.J., Schofield, C.J., Gil...
 
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Unreleased structure'''


The entry 8c8b is ON HOLD
==Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 48).==
<StructureSection load='8c8b' size='340' side='right'caption='[[8c8b]], [[Resolution|resolution]] 1.46&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[8c8b]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8C8B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8C8B FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.46&#8491;</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8c8b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8c8b OCA], [https://pdbe.org/8c8b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8c8b RCSB], [https://www.ebi.ac.uk/pdbsum/8c8b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8c8b ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/DCR1A_HUMAN DCR1A_HUMAN] May be required for DNA interstrand cross-link repair. Also required for checkpoint mediated cell cycle arrest in early prophase in response to mitotic spindle poisons.<ref>PMID:15542852</ref>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
The three human SNM1 metallo-beta-lactamase fold nucleases (SNM1A-C) play key roles in DNA damage repair and in maintaining telomere integrity. Genetic studies indicate that they are attractive targets for cancer treatment and to potentiate chemo- and radiation-therapy. A high-throughput screen for SNM1A inhibitors identified diverse pharmacophores, some of which were shown by crystallography to coordinate to the di-metal ion centre at the SNM1A active site. Structure and turnover assay-guided optimization enabled the identification of potent quinazoline-hydroxamic acid containing inhibitors, which bind in a manner where the hydroxamic acid displaces the hydrolytic water and the quinazoline ring occupies a substrate nucleobase binding site. Cellular assays reveal that SNM1A inhibitors cause sensitisation to, and defects in the resolution of, cisplatin-induced DNA damage, validating the tractability of MBL fold nucleases as cancer drug targets.


Authors: Yosaatmadja, Y., Newman, J.A., Baddock, H.T., Bielinski, M., von Delft, F., Bountra, C., McHugh, P.J., Schofield, C.J., Gileadi, O.
Cell-active small molecule inhibitors validate the SNM1A DNA repair nuclease as a cancer target.,Bielinski M, Henderson LR, Yosaatmadja Y, Swift LP, Baddock HT, Bowen MJ, Brem J, Jones PS, McElroy SP, Morrison A, Speake M, van Boeckel S, van Doornmalen E, van Groningen J, van den Hurk H, Gileadi O, Newman JA, McHugh PJ, Schofield CJ Chem Sci. 2024 Apr 30;15(21):8227-8241. doi: 10.1039/d4sc00367e. eCollection 2024 , May 29. PMID:38817593<ref>PMID:38817593</ref>


Description: Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 48).
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
[[Category: Unreleased Structures]]
</div>
[[Category: Yosaatmadja, Y]]
<div class="pdbe-citations 8c8b" style="background-color:#fffaf0;"></div>
[[Category: Bielinski, M]]
== References ==
[[Category: Von Delft, F]]
<references/>
[[Category: Baddock, H.T]]
__TOC__
[[Category: Gileadi, O]]
</StructureSection>
[[Category: Newman, J.A]]
[[Category: Homo sapiens]]
[[Category: Mchugh, P.J]]
[[Category: Large Structures]]
[[Category: Bountra, C]]
[[Category: Baddock HT]]
[[Category: Schofield, C.J]]
[[Category: Bielinski M]]
[[Category: Bountra C]]
[[Category: Gileadi O]]
[[Category: McHugh PJ]]
[[Category: Newman JA]]
[[Category: Schofield CJ]]
[[Category: Yosaatmadja Y]]
[[Category: Von Delft F]]

Latest revision as of 09:20, 11 September 2024

Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 48).Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 48).

Structural highlights

8c8b is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 1.46Å
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

DCR1A_HUMAN May be required for DNA interstrand cross-link repair. Also required for checkpoint mediated cell cycle arrest in early prophase in response to mitotic spindle poisons.[1]

Publication Abstract from PubMed

The three human SNM1 metallo-beta-lactamase fold nucleases (SNM1A-C) play key roles in DNA damage repair and in maintaining telomere integrity. Genetic studies indicate that they are attractive targets for cancer treatment and to potentiate chemo- and radiation-therapy. A high-throughput screen for SNM1A inhibitors identified diverse pharmacophores, some of which were shown by crystallography to coordinate to the di-metal ion centre at the SNM1A active site. Structure and turnover assay-guided optimization enabled the identification of potent quinazoline-hydroxamic acid containing inhibitors, which bind in a manner where the hydroxamic acid displaces the hydrolytic water and the quinazoline ring occupies a substrate nucleobase binding site. Cellular assays reveal that SNM1A inhibitors cause sensitisation to, and defects in the resolution of, cisplatin-induced DNA damage, validating the tractability of MBL fold nucleases as cancer drug targets.

Cell-active small molecule inhibitors validate the SNM1A DNA repair nuclease as a cancer target.,Bielinski M, Henderson LR, Yosaatmadja Y, Swift LP, Baddock HT, Bowen MJ, Brem J, Jones PS, McElroy SP, Morrison A, Speake M, van Boeckel S, van Doornmalen E, van Groningen J, van den Hurk H, Gileadi O, Newman JA, McHugh PJ, Schofield CJ Chem Sci. 2024 Apr 30;15(21):8227-8241. doi: 10.1039/d4sc00367e. eCollection 2024 , May 29. PMID:38817593[2]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

  1. Akhter S, Richie CT, Deng JM, Brey E, Zhang X, Patrick C Jr, Behringer RR, Legerski RJ. Deficiency in SNM1 abolishes an early mitotic checkpoint induced by spindle stress. Mol Cell Biol. 2004 Dec;24(23):10448-55. PMID:15542852 doi:http://dx.doi.org/24/23/10448
  2. Bielinski M, Henderson LR, Yosaatmadja Y, Swift LP, Baddock HT, Bowen MJ, Brem J, Jones PS, McElroy SP, Morrison A, Speake M, van Boeckel S, van Doornmalen E, van Groningen J, van den Hurk H, Gileadi O, Newman JA, McHugh PJ, Schofield CJ. Cell-active small molecule inhibitors validate the SNM1A DNA repair nuclease as a cancer target. Chem Sci. 2024 Apr 30;15(21):8227-8241. PMID:38817593 doi:10.1039/d4sc00367e

8c8b, resolution 1.46Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA